The University of Southampton
University of Southampton Institutional Repository

Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study

Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study
Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study
Objectives: to determine (1) the effectiveness and cost-effectiveness of selective serotonin reuptake inhibitor (SSRI) treatment plus supportive care, versus supportive care alone, for mild to moderate depression in patients with somatic symptoms in primary care; and (2) the impact of the initial severity of depression on effectiveness and relative costs. To investigate the impact of demographic and social variables.

Design: the study was a parallel group, open-label, pragmatic randomised controlled trial.

Setting: the study took place in a UK primary care setting. Patients were referred by 177 GPs from 115 practices around three academic centres.

Participants: patients diagnosed with new episodes of depression and potentially in need of treatment. In total, 602 patients were referred to the study team, of whom 220 were randomised.

Interventions: GPs were asked to provide supportive care to all participants in follow-up consultations 2, 4, 8 and 12 weeks after the baseline assessment, to prescribe an SSRI of their choice to patients in the SSRI plus supportive care arm and to continue treatment for at least 4 months after recovery. They could switch antidepressants during treatment if necessary. They were asked to refrain from prescribing an antidepressant to those in the supportive care alone arm during the first 12 weeks but could prescribe to these patients if treatment became necessary.

Main outcome measures: the primary outcome measure was Hamilton Depression Rating Scale (HDRS) score at 12-week follow-up. Secondary outcome measures were scores on HDRS at 26-week follow-up, Beck Depression Inventory, Medical Outcomes Study Short Form-36 (SF-36), Medical Interview Satisfaction Scale (MISS), modified Client Service Receipt Inventory and medical record data.

Results: SSRIs were received by 87% of patients in the SSRI plus supportive care arm and 20% in the supportive care alone arm. Longitudinal analyses demonstrated statistically significant differences in favour of the SSRI plus supportive care arm in terms of lower HDRS scores and higher scores on the SF-36 and MISS. Significant mean differences in HDRS score adjusted for baseline were found at both follow-up points when analysed separately but were relatively small. The numbers needed to treat for remission (to HDRS < 8) were 6 [95% confidence interval (CI) 4 to 26)] at 12 weeks and 6 (95% CI 3 to 31) at 26 weeks, and for significant improvement (HDRS reduction ? 50%) were 7 (95% CI 4 to 83) and 5 (95% CI 3 to 13) respectively. Incremental cost-effectiveness ratios and cost-effectiveness planes suggested that adding an SSRI to supportive care was probably cost-effective. The cost-effectiveness acceptability curve for utility suggested that adding an SSRI to supportive care was cost-effective at the values of £20,000–£30,000 per quality-adjusted life-year. A poorer outcome on the HDRS was significantly related to greater severity at baseline, a higher physical symptom score and being unemployed.

Conclusions: treatment with an SSRI plus supportive care is more effective than supportive care alone for patients with mild to moderate depression, at least for those with symptoms persisting for 8 weeks and an HRDS score of ? 12. The additional benefit is relatively small, and may be at least in part a placebo effect, but is probably cost-effective at the level used by the National Institute for Health and Clinical Excellence to make judgements about recommending treatments within the National Health Service. However, further research is required.
1366-5278
i-182
Kendrick, T.
c697a72c-c698-469d-8ac2-f00df40583e5
Chatwin, J.
c828a7b0-e6c6-4229-b7b3-384feb083b76
Dowrick, C.
62230e79-d957-4c6a-9c64-2b21dd7987cc
Tylee, A.
ca759e2d-ee8c-465d-b574-c0ff82ee4d47
Morriss, R.
30d5dc2c-4140-4181-9bbd-a70c6c9dcb17
Peveler, R.
93198224-78d9-4c1f-9c07-fdecfa69cf96
Leese, M.
17bd70c8-6255-4260-b595-57505b8596bd
McCrone, P.
46acaeda-f726-49ca-b83a-0ed61cac7f83
Harris, T.
36d8e752-4ee5-4f4c-8016-4defa753ea18
Moore, M.
1be81dad-7120-45f0-bbed-f3b0cc0cfe99
Byng, R.
2f69d048-e007-4a54-83fd-01ef1fa40da2
Brown, G.
c3b1457e-ccc4-4705-846f-8fbb63aa21a2
Barthel, S.
a1d59917-4544-4e3b-97bb-e1f3a0eea110
Mander, H.
eef567ad-e4b2-4f26-b782-16568d397280
Ring, A.
94c4eca4-5896-4af8-9686-be343647223f
Kelly, V.
aed61a73-8a38-48da-b20b-ccb88d4de389
Wallace, V.
0cabaa4e-97aa-4475-a72a-485a4e620f6b
Gabbay, M.
2368972c-3306-471f-bf13-42f70fd9833e
Craig, T.
9d729259-08f3-46bb-9a0f-8f0c8f40f32c
Mann, A.
337c3eda-df03-4695-90b1-0db68dad8918
Kendrick, T.
c697a72c-c698-469d-8ac2-f00df40583e5
Chatwin, J.
c828a7b0-e6c6-4229-b7b3-384feb083b76
Dowrick, C.
62230e79-d957-4c6a-9c64-2b21dd7987cc
Tylee, A.
ca759e2d-ee8c-465d-b574-c0ff82ee4d47
Morriss, R.
30d5dc2c-4140-4181-9bbd-a70c6c9dcb17
Peveler, R.
93198224-78d9-4c1f-9c07-fdecfa69cf96
Leese, M.
17bd70c8-6255-4260-b595-57505b8596bd
McCrone, P.
46acaeda-f726-49ca-b83a-0ed61cac7f83
Harris, T.
36d8e752-4ee5-4f4c-8016-4defa753ea18
Moore, M.
1be81dad-7120-45f0-bbed-f3b0cc0cfe99
Byng, R.
2f69d048-e007-4a54-83fd-01ef1fa40da2
Brown, G.
c3b1457e-ccc4-4705-846f-8fbb63aa21a2
Barthel, S.
a1d59917-4544-4e3b-97bb-e1f3a0eea110
Mander, H.
eef567ad-e4b2-4f26-b782-16568d397280
Ring, A.
94c4eca4-5896-4af8-9686-be343647223f
Kelly, V.
aed61a73-8a38-48da-b20b-ccb88d4de389
Wallace, V.
0cabaa4e-97aa-4475-a72a-485a4e620f6b
Gabbay, M.
2368972c-3306-471f-bf13-42f70fd9833e
Craig, T.
9d729259-08f3-46bb-9a0f-8f0c8f40f32c
Mann, A.
337c3eda-df03-4695-90b1-0db68dad8918

Kendrick, T., Chatwin, J., Dowrick, C., Tylee, A., Morriss, R., Peveler, R., Leese, M., McCrone, P., Harris, T., Moore, M., Byng, R., Brown, G., Barthel, S., Mander, H., Ring, A., Kelly, V., Wallace, V., Gabbay, M., Craig, T. and Mann, A. (2009) Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. Health Technology Assessment, 13 (22), i-182. (doi:10.3310/hta13220). (PMID:19401066)

Record type: Article

Abstract

Objectives: to determine (1) the effectiveness and cost-effectiveness of selective serotonin reuptake inhibitor (SSRI) treatment plus supportive care, versus supportive care alone, for mild to moderate depression in patients with somatic symptoms in primary care; and (2) the impact of the initial severity of depression on effectiveness and relative costs. To investigate the impact of demographic and social variables.

Design: the study was a parallel group, open-label, pragmatic randomised controlled trial.

Setting: the study took place in a UK primary care setting. Patients were referred by 177 GPs from 115 practices around three academic centres.

Participants: patients diagnosed with new episodes of depression and potentially in need of treatment. In total, 602 patients were referred to the study team, of whom 220 were randomised.

Interventions: GPs were asked to provide supportive care to all participants in follow-up consultations 2, 4, 8 and 12 weeks after the baseline assessment, to prescribe an SSRI of their choice to patients in the SSRI plus supportive care arm and to continue treatment for at least 4 months after recovery. They could switch antidepressants during treatment if necessary. They were asked to refrain from prescribing an antidepressant to those in the supportive care alone arm during the first 12 weeks but could prescribe to these patients if treatment became necessary.

Main outcome measures: the primary outcome measure was Hamilton Depression Rating Scale (HDRS) score at 12-week follow-up. Secondary outcome measures were scores on HDRS at 26-week follow-up, Beck Depression Inventory, Medical Outcomes Study Short Form-36 (SF-36), Medical Interview Satisfaction Scale (MISS), modified Client Service Receipt Inventory and medical record data.

Results: SSRIs were received by 87% of patients in the SSRI plus supportive care arm and 20% in the supportive care alone arm. Longitudinal analyses demonstrated statistically significant differences in favour of the SSRI plus supportive care arm in terms of lower HDRS scores and higher scores on the SF-36 and MISS. Significant mean differences in HDRS score adjusted for baseline were found at both follow-up points when analysed separately but were relatively small. The numbers needed to treat for remission (to HDRS < 8) were 6 [95% confidence interval (CI) 4 to 26)] at 12 weeks and 6 (95% CI 3 to 31) at 26 weeks, and for significant improvement (HDRS reduction ? 50%) were 7 (95% CI 4 to 83) and 5 (95% CI 3 to 13) respectively. Incremental cost-effectiveness ratios and cost-effectiveness planes suggested that adding an SSRI to supportive care was probably cost-effective. The cost-effectiveness acceptability curve for utility suggested that adding an SSRI to supportive care was cost-effective at the values of £20,000–£30,000 per quality-adjusted life-year. A poorer outcome on the HDRS was significantly related to greater severity at baseline, a higher physical symptom score and being unemployed.

Conclusions: treatment with an SSRI plus supportive care is more effective than supportive care alone for patients with mild to moderate depression, at least for those with symptoms persisting for 8 weeks and an HRDS score of ? 12. The additional benefit is relatively small, and may be at least in part a placebo effect, but is probably cost-effective at the level used by the National Institute for Health and Clinical Excellence to make judgements about recommending treatments within the National Health Service. However, further research is required.

Text
FullReport-hta13220.pdf - Version of Record
Restricted to Repository staff only
Request a copy

More information

Published date: April 2009
Additional Information: Trial registration: current controlled trials ISRCTN84854789
Organisations: Community Clinical Sciences

Identifiers

Local EPrints ID: 146879
URI: http://eprints.soton.ac.uk/id/eprint/146879
ISSN: 1366-5278
PURE UUID: 0987dcec-688a-4a72-a78c-ae6f2ad2d2ec
ORCID for T. Kendrick: ORCID iD orcid.org/0000-0003-1618-9381
ORCID for R. Peveler: ORCID iD orcid.org/0000-0001-5596-9394
ORCID for M. Moore: ORCID iD orcid.org/0000-0002-5127-4509

Catalogue record

Date deposited: 22 Apr 2010 14:58
Last modified: 14 Mar 2024 02:50

Export record

Altmetrics

Contributors

Author: T. Kendrick ORCID iD
Author: J. Chatwin
Author: C. Dowrick
Author: A. Tylee
Author: R. Morriss
Author: R. Peveler ORCID iD
Author: M. Leese
Author: P. McCrone
Author: T. Harris
Author: M. Moore ORCID iD
Author: R. Byng
Author: G. Brown
Author: S. Barthel
Author: H. Mander
Author: A. Ring
Author: V. Kelly
Author: V. Wallace
Author: M. Gabbay
Author: T. Craig
Author: A. Mann

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×